<DOC>
	<DOCNO>NCT01326000</DOCNO>
	<brief_summary>This randomize , multicenter , open label study evaluate safety efficacy RO5083945 combination FOLFIRI compare FOLFIRI plus cetuximab FOLFIRI alone second line treatment patient metastatic colorectal cancer . Patients randomize receive RO5083945 ( 1400 mg intravenously Day 1 Day 8 every 2 week thereafter ) plus FOLFIRI standard iv chemotherapy FOLFIRI plus cetuximab ( 400 mg/m2 iv Day 1 follow 250 mg/m2 iv every week ) FOLFIRI alone . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study RO5083945 Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab FOLFIRI Alone Second Line Treatment Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Carcinoma colon and/or rectum Disease progression within 6 month last dose oxaliplatin contain firstline combination therapy metastatic disease ECOG performance status 01 Adequate hematological , renal liver function Prior treatment monoclonal antibody/small molecule epidermal growth factor receptor ( EGFR ) Prior treatment irinotecan Radiotherapy within last 4 week first dose study drug ( except limit field palliative radiotherapy bone pain relief ) CNS metastasis History active autoimmune disorders/conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>